Differences in daily objective physical activity and sedentary time between women with self-reported fibromyalgia and controls: results from the Canadian health measures survey.

Physical activity and sedentary behaviors are important modifiable factors that influence health and quality of life in women with fibromyalgia. The purpose of this study was to compare objectively assessed physical activity and sedentary time in women self-reporting fibromyalgia with a control group. Data were drawn from the Canadian Health Measures Survey cycles 1, 2, and 3 conducted by Statistics Canada. We included women aged 18 to 79 years with complete accelerometer data. We performed one-way analyses of covariance (adjusted-for socio-demographic and health factors) to determine mean differences in physical activity and sedentary variables (minutes per day of moderate and vigorous physical activity, light physical activity, sedentary and daily steps) between women with and without fibromyalgia. In total, 4132 participants were included. A cross-sectional weighted analysis indicated that 3.1% of participants self-reported a diagnosis of fibromyalgia. Participants with fibromyalgia spent less time than controls engaged in moderate and vigorous physical activity (M = 19.2 min/day (SE = 0.7) versus M = 9.1 min/day (SE = 1.2), p = 0.03, η2 = 0.01). No significant differences were found for daily time spent in light physical activity, sedentary activities, and number of steps. Women participants with self-reported fibromyalgia spent significantly less time in moderate and vigorous physical activity than control. Physical activity promotion interventions for women with self-reported fibromyalgia should, as a priority, target physical activities with moderate to vigorous intensity.

Effect of structural compliance on cavitation threshold measurement of mechanical heart valves.

An in vitro study was designed to evaluate the effect of structural compliance on cavitation threshold measurements of mechanical heart valves. Using a dual channel high speed video image analysis method, the experiment was carried out in a pulse duplicator under a single, simulated physiologic condition. Each valve was mounted on a compliance adjustable fixture. One video camera served as a displacement monitor, while the other monitored cavitation bubbles at the inflow side of the valve. On-line adjustment of the mounting compliance allowed for cavitation threshold detection with respect to compliance without influencing the testing condition. Visible cavitation bubbles disappeared when the compliance was increased. Ten 29 mm mitral valves, including two each of St. Jude Medical, Carbomedics, Edwards-Duromedics (ED), Edwards Tekna (ET) and Medtronic-Hall (MH) were tested. All the bileaflet valves tested in this study showed similar cavitation thresholds at a compliance range of 0.5-0.65 mil/lb at a dp/dt of 4,000 mmHg/sec (averaged dp/dt during valve closure). Under the same dp/dt, MH monoleaflet valves showed a higher compliance range of 3.5-3.8 mil/lb to achieve the cavitation threshold. This study demonstrated that the mounting compliance of the valve must be known and well controlled in order to quantify the cavitation threshold with respect to dp/dt. In addition, the more compliant sewing ring of the ET valve may be responsible for higher cavitation thresholds with respect to dp/dt as observed in previous studies. The present in vitro study suggests that the investigation of the sewing structural compliance may be essential for the evaluation of in vivo cavitation potential.

An interlaboratory comparison of the FDA protocol for the evaluation of cavitation potential of mechanical heart valves.

Five laboratories carried out measurements of cavitation threshold for a common set of six mechanical prosthetic heart valves, two each from three different manufacturers. This study was intended to evaluate to what extent FDA's current guidance for cavitation testing would lead to consistent results in a variety of laboratory settings and to seek areas for improvement in the recommended test protocol. The inter-laboratory study protocol specified: (1) characterization of the test fluid by oxygen content and electrical conductivity, (2) location and frequency response of pressure sensors, (3) determination of ventricular and atrial pressures (P) and loading rates (dP/dt) averaged over the time period of valve closure and over the time periods of 1 ms, 5 ms, and 20 ms prior to video visualization. The protocol did not specify: (1) the fluid pumping equipment to be used to generate cavitation, (2) the pump or fluid parameters adjusted to raise or lower the loading rate, (3) the equipment, technique, or sensitivity used to visualize cavitation, and (4) a specific definition of the threshold for cavitation. Results from the five laboratories are reported. Significant differences in results were observed in dP/dt and in the pressure difference across the valves during closure at cavitation threshold. Specific differences in test systems included a wide range of ventricular compliance and single valved versus double valved test systems. Three single valve systems with compliant ventricles produced results in reasonable agreement with one another. Further similarity in test equipment should be specified to assure adequate interlaboratory reliability for cavitation testing. Areas needing better specification include the design of the valve mount, the design of the cavitation generators, and qualitative criteria for detection of threshold cavitation.

Quantitative determination of esters by saponification in dimethyl sulphoxide.

A method is given for the quantitative determination of esters which makes use of the unusually rapid rate of their alkaline hydrolysis in aqueous dimethyl sulphoxide medium. Only 5 min heating on a steam-bath is needed for quantitative hydrolysis of most esters, and many react completely in 5 min at room temperature. When hydrolysis is complete, the excess of base is titrated with standard acid, using a visual indicator.

A newly developed porcine heart valve bioprosthesis fixed with an epoxy compound. An experimental evaluation.

Concerns with currently available bioprostheses are calcification, long-term durability, and functional and hemodynamic performance. It has been well known that these concerns are all more or less related to the fixatives, glutaraldehyde or formaldehyde, used in preserving bioprostheses. To address these concerns, we undertook the development of a porcine bioprosthesis fixed with an epoxy compound. It was discovered that the porcine leaflets fixed with the epoxy compound appeared more natural than those preserved with glutaraldehyde. The performance of this newly developed epoxy compound bioprosthesis (three samples) was evaluated in a juvenile sheep model. The results were compared to those of its glutaraldehyde counterpart (three samples). Two-dimensional echocardiographic inspection of the valvular leaflet motion indicated that the epoxy compound leaflets were more pliable than their glutaraldehyde counterparts. In addition, the epoxy compound valve appeared to open more widely than the glutaraldehyde valve. Color Doppler flow mapping demonstrated that the blood flow distal to the epoxy compound valve was slightly broader than that observed distal to the glutaraldehyde valve. Moreover, at retrieval, less calcium and pannus ingrowth were observed in the epoxy compound valve than its glutaraldehyde counterpart. The results of this preliminary evaluation indicated that the performance of this newly developed epoxy compound valve was at least equivalent to its glutaraldehyde counterpart, if not better.

In vitro pulsatile flow evaluation of a stentless porcine aortic bioprosthesis.

Suboptimal hemodynamic performance, tissue calcification, and limitation in long-term durability have been encountered clinically after aortic valve replacement with currently available bioprostheses. It is believed that some of these problems may be caused, directly or indirectly, by the stents of the bioprostheses. To address these deficiencies, the authors undertook the development of the Edwards Prima Stentless Bioprosthesis. This study was designed to evaluate the hemodynamic performance of the Edwards Prima Stentless Bioprosthesis in a pulse duplicator system. The stented Carpentier-Edwards Porcine Bioprosthesis (Baxter Healthcare Corp., Irvine, CA), which has been used in United States clinics for more than 10 years, was used as a control device. The flow fields in the vicinity of the test bioprostheses were inspected with color Doppler flow mapping. The transvalvular pressure gradients were measured invasively with a catheter and calculated with the Doppler determined velocity using a simplified Bernoulli equation. Additionally, the leakage volumes were determined with an electromagnetic flowmeter. In the Doppler flow mapping study, during systole, a central flow was observed distal to the stentless and stented bioprostheses. The central flow distal to the stentless bioprosthesis was broader than that observed distal to its stented counterpart. During diastole, no regurgitation was detected by color Doppler flow mapping in either the stentless or stented groups. The Doppler determined transvalvular pressure gradients correlated well with those measured by catheter (r = 0.990). Moreover, it was learned that the transvalvular pressure gradients of the stentless bioprosthesis were less than those of its stented counterpart, especially for the smaller sizes.(ABSTRACT TRUNCATED AT 250 WORDS)

Cavitation threshold with respect to dP/dt: evaluation in 29 mm bileaflet, pyrolitic carbon heart valves.

A total of 15 bileaflet mechanical heart valves were studied in a pulse duplicator at the Helmholtz Institute (Aachen, Germany) under conditions approximating first, a physiological pressure curve and subsequently, a sinusoidal pressure curve. In this study Edwards-Duromedics valves of the modified specification were compared with the earlier version of the Edwards-Duromedics valve as well as with St. Jude Medical valves. Each valve was tested at a series of nine (9) conditions. At each condition, without altering the valve installation or the systemic conditions, each valve was filmed by two separate video systems: the Helmholtz Institute strobe light system and a high speed video recording system. All data, as recorded by each system, was then independently analyzed by both of the two contributing groups and subsequently compared. In this manner, it was possible to objectively verify not only the consistency of the data obtained, but to also determine the relative reliability of the methods for cavitation threshold detection.

In vitro pulsatile flow study on effective orifice area of prosthetic mechanical heart valves.

The effective orifice area (EOA) of a mechanical heart valve is an index of how well the valve design utilizes its primary orifice area (POA). In vitro measurements of EOA of aortic valves were maintained by means of pressure drop and root mean square flow rate measurements in a pulse duplicator during systole. Edwards-Duromedics, St. Jude Medical, and Carbomedics aortic valves of sizes 19 19 mm, 21 mm, 25 mm, and 27 mm were analyzed over a cardiac output range of 3 to 7 liters/min. The resultant ratios of EOA/POA were in the range of 0.6-0.8. A simplified equation suggested by the FDA was used in this study to calculate EOAs. To agree with original assumptions of the simplification, the entrance flow area (EFA) where upstream pressure is measured, must be large as compared to that of the test valves. If not, the formula can yield questionable results such as implying that the EOA can be larger than the POA (Walker P et al, 1992) [1]. This paper discusses the limitations in using such an equation. In conclusion, we suggest utilizing the parameter square root of 1-(POA/EFA)2 to evaluate the validity of the data processing, before using the equation. The parameter should be close to one, and in this study it was 0.997.

False-positive results obtained with the Alexon ProSpecT Cryptosporidium enzyme immunoassay.

Cryptosporidium is known to cause diarrhea in immunocompromised patients and is also associated with outbreaks of disease due to food-borne and waterborne parasites. Traditional procedures, involving iodine staining of wet mounts of stool sediments and trichrome staining, lack the sensitivity to detect Cryptosporidium. Special staining procedures, such as the modified acid-fast and safranin stains, are generally employed. Less labor-intensive antigen detection assays have simplified detection; however, careful attention to local epidemiology is important because false-positive tests occur. Here, we report two incidents involving 62 false-positive results obtained with the Alexon ProSpecT Cryptosporidium enzyme immunoassay, which were deemed false-positive based on negative results obtained from extensive microscopic examinations.

In vitro evaluation of a stentless porcine aortic bioprosthesis. A preliminary study.

Currently available aortic bioprosthetic heart valves are all relatively suboptimal due to the constraints placed on leaflets by stenting. The constraints on the stenting mechanism may directly or indirectly cause turbulence in the orifice neighborhood, be nidi of tissue calcification, and impart transleaflet stress differentials. To address all these deficiencies, we undertook the development of a stentless porcine aortic bioprosthesis (SPAB). This study evaluates the hemodynamic performance and durability of this design in special chambers with near physiologic compliance. The results are compared to those shown by a stented porcine aortic bioprosthesis. The pressure measurements under steady flow conditions showed that the hemodynamic performance (including pressure gradient and effective orifice area) of SPAB is superior to that of its stented counterpart, especially in the smaller sizes. In addition, it is expected that this stentless design should minimize the mechanical stress to which the leaflets are subjected throughout the cardiac cycle, thus enhancing the durability of the bioprosthesis. In our accelerated durability study for up to 2 equivalent years, no valve failure has been observed. More in vitro studies under pulsatile flow conditions, including color Doppler flow visualization, are currently being conducted.